Spots Global Cancer Trial Database for neoantigen
Every month we try and update this database with for neoantigen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | NCT03568058 | Advanced Cancer | personalized va... Pembrolizumab | 18 Years - | University of California, San Diego | |
| Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors | NCT05359354 | Solid Tumor | Personalized ne... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | NCT03871205 | Carcinoma, Non-... Carcinoma, Smal... | Neoantigen load... | 18 Years - 70 Years | Shenzhen People's Hospital | |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | NCT03970382 | Solid Tumor | NeoTCR-P1 adopt... nivolumab IL-2 | 18 Years - | PACT Pharma, Inc. | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | NCT04267237 | Non-small Cell ... | Atezolizumab RO7198457 | 18 Years - | Hoffmann-La Roche | |
| Neoantigen Derived DCs as Cancer Treatment | NCT05767684 | Refractory Tumo... Solid Tumor | Dendritic Cell ... Lenvatinib Nivolumab | 20 Years - | National Health Research Institutes, Taiwan | |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | NCT02897765 | Urinary Bladder... Bladder Tumors Transitional Ce... Malignant Melan... Melanoma Skin Cancer Carcinoma, Non-... Lung Cancer | NEO-PV-01 Nivolumab Adjuvant | 18 Years - | BioNTech SE | |
| Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers | NCT05153304 | Cancer of Gastr... | personalized va... Nivolumab | 18 Years - | University of California, San Diego | |
| Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer | NCT05270720 | Recurrent Ovari... | dendritic cell | 18 Years - 75 Years | West China Second University Hospital | |
| Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | NCT05798533 | Solid Tumor | Neo-T Toripalimab Tislelizumab | 18 Years - 75 Years | BGI, China | |
| Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | NCT03871205 | Carcinoma, Non-... Carcinoma, Smal... | Neoantigen load... | 18 Years - 70 Years | Shenzhen People's Hospital | |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | NCT03597282 | Metastatic Mela... | NEO-PV-01 Nivolumab Adjuvant APX005M ipilimumab | 18 Years - | BioNTech SE | |
| Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) | NCT05798546 | Solid Tumor | Neo-T Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - 75 Years | BGI, China | |
| Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms | NCT06026800 | Digestive Syste... | iNeo-Vac-R01 | 18 Years - 75 Years | Sir Run Run Shaw Hospital | |
| Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | NCT05798533 | Solid Tumor | Neo-T Toripalimab Tislelizumab | 18 Years - 75 Years | BGI, China | |
| Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) | NCT05798546 | Solid Tumor | Neo-T Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - 75 Years | BGI, China | |
| Safety and Immune Response to FMPV-1 | NCT05238558 | Colorectal Canc... | FMPV-1 GM-CSF (as adju... | 18 Years - 55 Years | Hubro Therapeutics AS | |
| Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer | NCT06344156 | Pancreatic Canc... Adjuvant Therap... | Neoantigen Vacc... | 18 Years - 75 Years | Sichuan University | |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | NCT03380871 | Carcinoma, Non-... Lung Cancer Nonsquamous Non... | NEO-PV-01 Pembrolizumab Adjuvant Carboplatin Pemetrexed | 18 Years - | BioNTech SE | |
| Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers | NCT05153304 | Cancer of Gastr... | personalized va... Nivolumab | 18 Years - | University of California, San Diego | |
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab | NCT04266730 | Squamous Cell L... Squamous Non-sm... Squamous Cell C... | PANDA-VAC Pembrolizumab | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors | NCT05359354 | Solid Tumor | Personalized ne... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC | NCT05317325 | Esophageal Squa... | OCDC vaccine; N... | 18 Years - 80 Years | Sichuan University | |
| Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors | NCT03171220 | Advanced Malign... | Neoantigen Reac... SHR-1210 Fludarabine Cyclophosphamid... Interleukin-2 | 18 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers | NCT03568058 | Advanced Cancer | personalized va... Pembrolizumab | 18 Years - | University of California, San Diego | |
| Clinical Trial on Personalized Neoantigen Vaccine for Pancreatic Tumor | NCT03558945 | Pancreatic Tumo... | Personalized ne... | 20 Years - 75 Years | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | |
| Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor | NCT03662815 | Advanced Malign... | iNeo-Vac-P01 GM-CSF | 18 Years - 75 Years | Sir Run Run Shaw Hospital | |
| Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens | NCT05498168 | Esophageal Canc... Neoantigen | ratio of predic... | 15 Years - 90 Years | University Medical Center Ho Chi Minh City (UMC) | |
| A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC | NCT05317325 | Esophageal Squa... | OCDC vaccine; N... | 18 Years - 80 Years | Sichuan University | |
| A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma | NCT03674073 | Hepatocellular ... Liver Cancer, A... | Neoantigen Vacc... Microwave Ablat... | 18 Years - | Chinese PLA General Hospital | |
| Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | NCT05194735 | Gynecologic Can... Colorectal Canc... Pancreatic Canc... Non-small Cell ... Cholangiocarcin... Ovarian Cancer Endometrial Can... Ovarian Carcino... Ovary Neoplasm Squamous Cell L... Adenocarcinoma ... Adenosquamous C... | Neoantigen spec... Aldesleukin (IL... | 18 Years - | Alaunos Therapeutics | |
| Immune Modulatory DC Vaccine Against Brain Tumor | NCT03914768 | Diffuse Intrins... | Immunomodulator... | 1 Year - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab | NCT04266730 | Squamous Cell L... Squamous Non-sm... Squamous Cell C... | PANDA-VAC Pembrolizumab | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) | NCT05798546 | Solid Tumor | Neo-T Cyclophosphamid... Fludarabine Interleukin-2 | 18 Years - 75 Years | BGI, China | |
| Safety and Immune Response to FMPV-1 | NCT05238558 | Colorectal Canc... | FMPV-1 GM-CSF (as adju... | 18 Years - 55 Years | Hubro Therapeutics AS | |
| Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes) | NCT02959905 | Solid Cancer | TSA-CTL Cyclophosphamid... Fludarabine Cyclophosphamid... | 18 Years - 70 Years | BGI, China | |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | NCT04596033 | Melanoma Non-small Cell ... Squamous Cell C... Urothelial Carc... Renal Cell Carc... Small-cell Lung... Cutaneous Squam... Anal Squamous C... Merkel Cell Car... | GEN-011 IL-2 Fludarabine Cyclophosphamid... | 18 Years - | Genocea Biosciences, Inc. | |
| A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | NCT03289962 | Melanoma Non-Small Cell ... Bladder Cancer Colorectal Canc... Triple Negative... Renal Cancer Head and Neck C... Other Solid Can... | Autogene cevume... Atezolizumab | 18 Years - | Genentech, Inc. | |
| Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION) | NCT04923802 | Non-small Cell ... Neoantigen Next-generation... Biomarker | 18 Years - 75 Years | GeneCast Biotechnology Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
